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Materials & Methods 
Generation of KO lines of kisspeptin related genes 
We generated kiss1 gene KO medaka using TALEN (1), while we generated kiss2, gpr54-1, gpr54-2 KO medaka using 
CRISPR/Cas9 (2). The specific TALEN and CRISPR/Cas9 target sites were identified using an online tool (ZiFiT: supplied 
by ZINC FINGER CONSORTIUM; http://www.zincfingers.org/default2.htm). Exon 3 of kiss1 gene and exon 2 of kiss2 gene, 
which code the core sequence of kisspeptin, were selected for target sites (Supplemental Figure 1, 2). Exon 4 of gpr54-1 gene, 
which codes the transmembrane region, was selected for the CRISPR target site (Supplemental Figure 3). Approximately 50 
bp downstream of the first methionine of gpr54-2 was selected for the CRISPR target site (Supplemental Figure 4). Gene-
specific TALEN constructs were assembled using Joung Lab REAL Assembly TALEN kit (Addgene, Cambridge, MA, USA) 
as described (1). TALEN coding region was transferred to pCold II (Takara), which contains the cold shock promoter, His- 
tag, and polyadenylation signal. NiCo21 (DE3) E. coli cells (NEB, Ipswich, MA, USA) were transfected by TALEN 
expression plasmid. TALEN proteins were purified by His-bind column (BIO-RAD, CA, USA) and by Heparin 
chromatography (QIAGEN, Hilden, Germany). For generation of gRNA, Oligo DNA (2μM) for gRNA listed in Table 1 were 
annealed and ligated with gRNA expression vector (DR274; Addgene) digested by BsaI (NEB) according to Hwang et al., 
2013. After cloning and digestion by DraI (NEB), gRNA was transcribed by T7 polymerase (Roche, Molecular Biochemicals 
GmbH, Mannheim, Germany). The Cas9 mRNA was transcribed using PmeI-digested Cas9 expression vector (MLM 3613; 
Addgene) by mMessage mMachine T7 ULTRA kit (Life technologies). EGFP mRNA was transcribed using SP6 promoter in 
linearized pCS2+EGFP vector. TALEN solution containing left and right TALEN protein, or CRISPR/Cas9 solution 
containing gRNA (12.5 ng/μL) and Cas9 mRNA (300 ng/μL), with EGFP mRNA (1-5ng/μL; for validation of successful 
microinjection) and 0.02 % phenol red in 1 x PBS were injected into the cytoplasm of fertilized one-cell stage medaka eggs 
with intact chorion. Genomic DNA of F1 fish was extracted from the caudal fin using Mag Extractor -Genome- (TOYOBO 
CO, Tokyo, Japan) or prepGem-tissue (ZyGEM, Hamilton, New Zealand) according to the respective manufacturer’s 
instructions. Amplicon that include the target region of each gene was generated by PCR using LightCycler 480 SYBER 
Green I Master (Roche), Thunderbird SYBR qPCR Mix (TOYOBO CO) and corresponding primers (Table 2). Candidate fish 
were chosen by comparing the peaks of the melting curves between wild type and F1 fish. After PCR reaction, primers were 
digested by Exonuclease I (Takara, Shiga, Japan), and dNTPs were dephosphorylated by Shrimp Alkaline Phosphatase 
(Takara). Amplicons of the candidate fish were sequenced by a commercial company (Fasmac, Kanagawa, Japan or Eurofins 
genomics, Tokyo, Japan). F1 fish that had mutation were intercrossed. Homozygous KO F2 fish were selected by genome 
sequence as described above. 
 
Luciferase Assays 
The luciferase assay experiments were performed as described previously in Kanda et al., 2013. The cDNA fragments 
containing full-length open reading frames of gpr54-1 and gpr54-2 were subcloned into the expression vector pcDNA3.1 
(Invitrogen). COS-7 cells were grown on 24-well plate at 37°C in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% fetal bovine serum. The plasmid DNAs (100 ng/well) were transfected into monolayer culture cells 
with either pSRE-Luc or pCRE-Luc (100 ng/well; Clontech, Palo Alto, CA), and pRL-CMV containing the Renilla luciferase 
reporter gene (2.5 ng/well; Promega, Madison, WI), using Lipofectamine LTX (Invitrogen). The cells were maintained in a 
serum-free medium for 24 hours. After that, they were incubated with various concentrations (from 0 to 10-6 M) of medaka 
Kiss1, Kiss2, or FTM145 for six hours and then harvested and analyzed. Luciferase activity in the cell extract was measured 
using Dual-Glo Luciferase Assay System (Promega) with Lumat LB9507 (EB & G Berthold, Bad Wildbad, Germany). The 
transfection experiments were performed in more than triplicate and were repeated at least three times. 
 in vivo administration of drugs 
LHRH-A (synthetic Luteinizing Hormone-Releasing Hormone analog; [des-Gly10, D-Ala6]-LH-RH ethylamide acetate salt 
hydrate) was dissolved in a fish saline (0.7% NaCl solution) and was injected i.p. (0.1μg/g BW (body weight)). Pimozide 
(PIM) was suspended in a vehicle of 0.7% NaCl with 0.1% sodium metabisulfite and was injected i.p. at 10 μg/g BW. The 
control groups were given an equivalent volume of saline and/or the PIM vehicle. The decapeptide of medaka Kiss1 (Kiss1-
10: YNLNSFGLRY-NH2) and the dodecapeptide of medaka Kiss2 (Kiss2-12: SKFNYNPFGLRF-NH2) were synthesized 
(Sigma-Aldrich Japan, Tokyo, Japan; Bonac Corporation, Kurume, Japan, respectively). Synthetic Kiss1-10 and FTM145 (4-
fluorobenzoyl-Phe-Gly-ψ[(E)-CH=CH]-Leu-Arg-Trp-NH2; GPR54 agonist (3-6) was dissolved in saline and injected i.p. (0.1 
μg or 1 μg/g BW) or i.c.v. (0.1nmol). Note that we initially confirmed by luciferase assay that FTM145 possesses binding 
affinities and efficacies to both of medaka Gpr54-1 and Gpr54-2 (Supplemental Figure 5B, D). Synthetic Kiss2-12 was first 
dissolved in DMSO and diluted with saline (0.02% DMSO in final concentration) and was injected i.p. (0.1 μg /g BW) or 
i.c.v. (0.1 nmol). 
In the experiments, the animals were divided into three groups: 1) those receiving i.p. administration on a short time scale, 
2) those receiving i.p. administration on a long time scale, and 3) those receiving i.c.v. administration. Ovulation was checked 
by the release of a stream of ripe translucent oocytes from the ovipore following application of a slight pressure to the abdomen 
(7). In Group 1 (i.p. administration of a long time scale), PIM was injected 12 hours prior to the co-injection of peptide and 
PIM (0h) according to the previous study in goldfish using LHRH-A (8), and the blood was sampled just before the first 
injection of PIM (-12h), 24 hours and 48 hours after peptide injection (Figure 1A). In Group 2 (i.p. administration of a short 
time scale), PIM was injected three hours prior to the co-injection of peptide and PIM according to the previous study in 
goldfish using kisspeptin (9), and the blood was sampled just before the injection of peptide and PIM (0h), two hours and six 
hours after that (Supplemental Figure 8). In Group 3 (i.c.v. administration), PIM was injected i,p, 12 hours prior to the i.c.v. 
injection of peptide (0h), and the blood was sampled just before the first injection of PIM (-12h), just before the injection of 
peptide (0h), 0.5 hour and 3 hours after peptide injection. In all experiments, ovulation was checked until three days after the 
peptide injection (Supplemental Figure 9). 
 
Hematoxylin and eosin (HE) staining of gonads 
The ovaries and testes (90 dph (days post-hatch)) were fixed with Bouin's fixative at 4°C overnight. After fixation, each 
tissue sample was routinely processed and embedded in paraffin, and sections of 8 μm thickness were stained with 
hematoxylin and eosin (HE). Photographs were taken with a digital camera (DFC310FX; Leica Microsystems, Wetzlar, 
Germany) attached to an upright microscope (DM5000B; Leica Microsystems). 
 
Quantitative PCR 
Three-month-old medaka were deeply anesthetized with 0.02% MS-222, and the pituitaries were collected for real-time PCR 
analysis at 10 A.M.. Total RNA was extracted from the pituitaries using the NucleoSpin RNA XS (Takara, Shiga, Japan) or 
the brain using the NucleoSpin II (Takara) according to the manufacture’s protocol. Genomic DNA was removed by 
deoxyribonuclease I (Ambion, Applied Biosystems, Foster City, CA) treatment on a column membrane. Total RNA was 
reverse transcribed with High Capacity PrimeScript Reverse Transcriptase (Takara) according to the manufacturer’s 
instructions. For real-time PCR, the cDNA was amplified using Thunderbird SYBR qPCR Mix (TOYOBO CO) or KAPA 
SYBR FAST qPCR Kit (Nippon Genetics Co, LTD, Tokyo, Japan) with the LightCycler 480 II system (Roche). The 
temperature profile of the reaction was 95°C for 5 min, 45 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 10 
s, and extension at 72°C for 10 s. The PCR product was verified using melting curve analysis. The data were normalized to a 
housekeeping gene, ribosomal protein s13 (rps13). The primer pairs used in the real-time PCR are listed in Table 2. 
 
Ca2+ imaging of LH:IP cells  
We performed Ca2+ imaging using the whole brain-pituitary preparations from lhb:IP or lhb:IP;gnrh1:EGFP transgenic 
medaka (four males and five females) as we described previously (10). Positions of the LH cells were visually identified under 
epifluorescence illumination, and fluorescence images of IP were recorded (exposure: 100ms; interval: 5 s). In all experiments 
repetitively applying (2-3 times each) mdKiss1-10 and mdGnRH1 (medaka GnRH1) to one preparation for 5-6 min 
(Supplemental Figure 10), the intervals (washout time) between every two application trials were 10-30 minutes. For data 
analysis, we selected 27-50 ROIs (region of interest) and calculated their responses as follows. The time when drug reached 
the experimental chamber was defined as Frame 0 (F0). F0 was calculated as an average of five frames; Frame -8 to -4. The 
fluorescence intensity change (ΔF/F0) was calculated as (F0 -F)/F0, and the peak ΔF/F0 was picked up from 25 frames; Frame 
-3 to 21. As for the period before the first peptide application trial, we calculated F0 as average of Frame -52 to -48, and 
picked up peak ΔF/F0 from Frame -60 to -40. We excluded the data from one male fish because its LH cells showed severely 
weak IP fluorescence and did not respond to medaka GnRH1 application. 
 
Specificity of EGFP labeling on gpr54-1 expressing cells 
In order to confirm the specificity of EGFP expression in gpr54-1 expressing cells, we performed dual labeling of EGFP 
immunohistochemistry (IHC) and gpr54-1 mRNA in situ hybridization (ISH) on frozen brain sections of this transgenic 
medaka. A gpr54-1-specific digoxigenin (DIG)-labeled mRNA probe was prepared and applied to IHC and ISH procedures, 
following a standard protocol that we documented previously (10-12) with some minor modifications. Briefly, adult male and 
female medaka were anesthetized by immersion in 0.02% tricaine methanesulfonate (MS-222) (Sigma-Aldrich, Darmstadt, 
Germany) and quickly decapitated or fixed by perfusion with 4% paraformaldehyde (Nacalai Tesque, Japan) in PBS (Takara, 
Japan). The whole brains were quickly dissected out and fixed with 4% paraformaldehyde in PBS for 2-6 hours (without 
perfusion fixation) or 10-15 min (after perfusion fixation), and then substituted with 30 % (w/v) sucrose (Wako, Japan) in 
PBS overnight. Frontal sections (20-30 μm) were prepared by using a cryostat (CM 3050S; Leica Microsystems, Wetzlar, 
Germany), and mounted onto MAS-GP typeA-coated glass slides (Matsunami, Osaka, Japan). To detect EGFP-
immunoreactive (EGFP-ir) cells, we used anti-EGFP antibody raised in rabbit (13) (1:1000; generous gift from Dr. Kaneko 
and Dr. Hioki, Kyoto University, Kyoto, Japan, or Thermo Fisher Scientific, A-11122). To detect gpr54-1 mRNA, the sections 
were hybridized with 100-200 ng/ml DIG-labeled antisense cRNA probes prepared from the medaka brain cDNA samples 
using a labeling kit (Roche Applied Science, Mannheim, Germany) overnight at 58°C. A sense cRNA probe was used as 
negative controls. For dual-fluorescent visualization steps of IHC and ISH signals, AlexaFluor488 conjugated anti-rabbit IgG 
(1:500; Invitrogen, Carlsbad, CA) and HNPP/FastRed (HNPP Fluorescent Detection Set);(Roche Applied Science, Mannheim, 
Germany) were applied respectively. The sections were observed by a DM5000 B fluorescence microscope (Leica) and a 
LSM-710 confocal laser-scanning microscope (Carl Zeiss, Oberkochen, Germany) for the examination of co-localization for 
gpr54-1 mRNA and EGFP. 
 
Deep sequencing of gpr54-1:EGFP expressing cells 
The whole brains of adult male and female medaka were prepared as described above and placed in silicone-bottom dish 
filled with an artificial cerebrospinal fluid (ACSF) consisting of (in mM) 134 NaCl, 2.9 KCl, 1.2 MgCl2, 2.1 CaCl2, 10 HEPES, 
and 15 glucose (pH 7.4, adjusted with NaOH). Whole-brain in vitro preparations were carefully peeled off the meninges 
covering the telencephalon and hypothalamus in ACSF. Next, we identified gpr54-1 expressing cells by their EGFP 
fluorescence under an upright fluorescent microscope with infrared-differential interference contrast optics (Eclipse E-600FN; 
Nikon) and an infrared charge-coupled device camera (C3077–78; Hamamatsu Photonics). Then we collected five EGFP-
positive cells in ventrolateral preoptic area (vPOA) by suction of the pipettes made from borosilicate glass capillaries of 1.5 
mm outer diameter (GD-1.5; Narishige, Tokyo, Japan). The pipettes were pulled using a Flaming-Brown micropipette puller 
(P-97; Sutter Instruments, Novato, CA, USA) and we approached the tip of the pipette close to the cells by MP-225 
micromanipulator (Sutter Instrument, California, USA). The resistances of the pipette tips for cell collection were 
approximately 2–5 MΩ. For collecting the cells in area ventralis telencephali pars dorsalis/supracommissuralis/posterior 
(Vd/Vs/Vp), nucleus preopticus pars magnocellularis/parvocellularis (POm, POp), and nucleus posterioris periventricularis 
(NPPv), we sectioned the whole brain frontally by vibratome and the cells were dissociated by Papain solution (Roche Applied 
Science, Mannheim, Germany) and collected likewise under an inverted fluorescence microscope. We prepared the mixed 
sample containing 10 cells collected from Vd/Vs/Vp, vPOA, and hypothalamus (mixed 5 cells each from male and female) 
and performed the following lysis, reverse transcription (RT), and purification steps using SuperScript III (Thermo Fisher 
Scientific, MA, USA) and Nucleospin Gel and PCR clean-up kit (Macherey-Nagel, Berlin, Germany). cDNA libraries were 
obtained by these procedures mainly based on the standard protocol provided by Life Technologies, and then applied for the 
next generation sequencer Ion PGM (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA), following the 
standard protocol of Ion PGM system. We selected the candidate genes judging from reads per kilobase of exon per million 
mapped sequence reads (RPKM) for expression value in the obtained data. 
 
The nomenclature of the medaka brain nuclei 
ca/ch/cp/ct, commissura anterior/horizontalis/posterior/transversa; CE, corpus cerebelli; Dc/Dm/Dl/Dp, area dorsalis 
telencephali pars centralis/medialis/lateralis/posterior; DM, nucleus dorsomedialis thalami; flm, fasciculus longitudinalis 
medialis; fr, fasciculus retroflexus; GR, corpus glomerulosum pars rotunda; HB, habenula; lfb, lateral forebrain bundle; mfb, 
medial forebrain bundle; NAT, nucleus anterior tuberis; NC, nucleus corticalis; NDTL, nucleus diffusus tori lateralis; NIP, the 
interpeduncular nucleus; NPPv, nucleus posterioris periventricularis; NVT, nucleus ventralis tuberis; PGm, nucleus 
preglomerulosus pars medialis; POm/POp, nucleus preopticus pars magnocellularis/parvocellularis; pTGN, preglomerular 
tertiary gustatory nucleus; PTH, nucleus prethalamicus; TO, tectum opticum; TL/TS, torus longitudinalis/semicircularis; 
Vd/Vs/Vp/Vi/Vv, area ventralis telencephali pars dorsalis/supracommissuralis/posterior/intermedia/ventralis VM, nucleus 
ventromedialis thalami. 
 
Supplemental Figure legends 
 
Supplemental Figure 1.  Genomic and deduced amino acid sequences of wild type (wt) and TALEN knockout 
(KO) kiss1 gene. A, Alignment of genomic DNA sequences of kiss1 open reading frame (ORF) region of wt and 
kiss1 KO lines. Underlines indicate left and right TALEN targets. B, Alignment of deduced amino acid sequences 
of precursor of Kiss1 from genomic data of wt and kiss1 KO lines. Shaded region indicates kisspeptin core-peptide 
sequence. D; deletion, I; insertion, R; replacement. 
 
Supplemental Figure 2.  Genomic and deduced amino acid sequences of wt and CRISPR/Cas9 KO kiss2 gene. 
A, Alignment of genomic DNA sequences of kiss2 ORF region of wt and kiss2 KO lines. Underline indicates gRNA 
target. B, Alignment of deduced amino acid sequences of precursor of Kiss2 from genomic data of wt and kiss2 
KO lines. Shaded region indicates kisspeptin core-peptide sequence. D; deletion. 
 
Supplemental Figure 3.  Genomic and deduced amino acid sequences of wt and CRISPR/Cas9 KO gpr54-1 
gene. A, Alignment of genomic DNA sequences of gpr54-1 ORF region of wt and a gpr54-1 KO line. Underline 
indicates gRNA target. B, Alignment of deduced amino acid sequences of precursor of Gpr54-1 from genomic data 
of wt and a gpr54-1 KO line. Shaded region indicates transmembrane domain (TM). D; deletion, R; replacement. 
 
Supplemental Figure 4.  Genomic and deduced amino acid sequences of wt and CRISPR/Cas9 KO gpr54-2 
gene. A, Alignment of genomic DNA sequences of gpr54-2 ORF region of wt and gpr54-2 KO lines. Underline 
indicates gRNA target. B, Alignment of deduced amino acid sequences of precursor of Gpr54-2 from genomic data 
of wt and gpr54-2 KO lines. Shaded region indicates transmembrane domain (TM). D; deletion, I; insertion, R; 
replacement. 
 
Supplemental Figure 5.  Luciferase assays for the activation of two types of receptors, Gpr54-1 and Gpr54-2, 
by GPR54 agonist, FTM145 and synthetic kisspeptins showing their activation of Gpr54-1/2. A, Comparison of 
amino acid sequences of predicted mature kisspeptin in medaka and goldfish and FTM145. B-E, Medaka Gpr54-
1 (B, C) or Gpr54-2 (D, E) cDNA was transfected to COS-7 cells with SRE-luc or CRE-luc vector. Various 
concentrations of FTM145 (B, D) and medaka Kiss1-10, and medaka Kiss2-12 (C, E) were applied to the culture 
medium, and the luciferase activity was measured. The results are indicated as mean±SEM, each of which was 
conducted in more than triplicates. The data are expressed as the ratio of changes in luciferase activity over the 
control renilla luciferase activity. (C) and (E) were modified from Kanda et al., 2013. 
 
Supplemental Figure 6.  Hematoxylin and eosin (HE)-stained sections of ovaries (90 dph, left column) or testes 
(90 dph, right column) of kiss1, kiss2, gpr54-1, or gpr54-2 KO medaka. A-F, Ovaries (1) and testes (2) of wt (A), 
kiss1-/- (B), kiss2-/- (C), kiss1-/-;kiss2-/- (D), gpr54-1-/- (E), and gpr54-2-/- (F). PV; previtellogenic, LV; late vitellogenic, 
FG; full-grown, SG; spermatogonia, SC; spermatocyte, and SZ; spermatozoa. Scale bars, 500 μm (ovary) or 50 
μm (testis). 
 
Supplemental Figure 7.  Normal expression levels of gonadotropin genes in the KO medaka. A-B, Relative 
expression levels of lhb (A) and fshb (B) mRNA in the pituitary of wt male, kiss1-/- male, wt female, and kiss1-/- 
female. C-D, Relative expression levels of lhb mRNA in the pituitary of kiss1+/-;kiss2-/-, kiss1+/-;kiss2+/-, kiss1-
/- ;kiss2-/-, gpr54-1-/-, gpr54-1+/- (only in C), gpr54-2-/-, gpr54-2+/-, and wt male (C) and female (D). E-F, Relative 
expression levels of fshb mRNA in the pituitary of kiss1+/-;kiss2-/-, kiss1+/-;kiss2+/-, kiss1-/- ;kiss2-/-, gpr54-1-/-, gpr54-
1+/- (only in E), gpr54-2-/-, gpr54-2+/-, and wt male (E) and female (F). All the values were normalized to rps13. 
 
Supplemental Figure 8.  Plasma LH levels and % ovulated fish after intraperitoneal (i.p.) administration of 
kisspeptins and LHRH-A on a short time scale in goldfish showing no effect of kisspeptins. A, Experimental 
procedure for i.p. administration on a short time scale. B, Plasma LH levels (ng/mL) at 0 hour (h), 2 h and 6 h from 
peptides administration and % ovulated fish 60 h after peptide administrations. Note that only LHRH-A increased 
plasma LH levels and induced ovulation. PIM; pimozide, LHRH-A; luteinizing hormone releasing hormone analog. 
 
Supplemental Figure 9.  Plasma LH levels and % ovulated fish after intracerebroventricular (i.c.v.) administration 
of kisspeptins in goldfish showing no effect of kisspeptins. A, Experimental procedure for i.c.v. administration. B, 
Plasma LH levels (ng/mL) at -12 h, 0 h, 0.5 h and 3 h from peptide administrations and % ovulated fish 60 h after 
peptide administrations. 
 Supplemental Figure 10.  Ca2+ imaging of LH:IP cells showing no effect of kisspeptin on Ca2 rise for LH release. 
A, A representative picture of the analyzed LH cells in lhb:IP transgenic medaka (10 yellow circles, region of 
interest (ROI)) corresponding to the graphs shown in B. Scale bar, 50 μm. C, caudal; R, rostral. B, Representative 
traces of Ca2+ responses to 1 μM mdKiss1-10 (left graph, blue) or 1 μM mdGnRH1 (right graph, red) application. 
The graphs show the traces from 10 ROIs (thin lines) and the averaged traces (thick lines). C, The graph showing 
the averaged peak amplitudes of Ca2+ responses of LH cells to 1 μM mdKiss1-10 (blue) or 1 μM mdGnRH1 (red) 
applications in three male (Black circles) and five female (white circles) fish. Compared to the “Before” group 
(male: n=3, female: n=5), Kiss1-10 group (male: n=6, female: n=10) did not affect Ca2+ responses of LH cells, 
whereas GnRH1 group (male: n=6, female: n=14) significantly facilitated them as we previously reported in Karigo 
et al., 2014. Note that there is no significant difference between male and female. ***: p<0.001, Steel’s multiple 
comparison test. 
 
Supplemental Movie.  Representative 3D movie of whole mount IHC using the gpr54-1:EGFP transgenic 
medaka showing heavy projection from POA to the pituitary. The dense EGFP-ir fibers are mainly localized in the 
pars distalis and intermedia of the pituitary. The orientation of the first frame is the same in Figure 3E. 
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